PubMed:32491073 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":603,"end":608},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7088"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":603,"end":608},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":14,"end":38},"obj":"Disease"},{"id":"T2","span":{"begin":42,"end":65},"obj":"Disease"},{"id":"T3","span":{"begin":136,"end":160},"obj":"Disease"},{"id":"T4","span":{"begin":162,"end":170},"obj":"Disease"},{"id":"T5","span":{"begin":252,"end":260},"obj":"Disease"},{"id":"T6","span":{"begin":377,"end":385},"obj":"Disease"},{"id":"T7","span":{"begin":419,"end":430},"obj":"Disease"},{"id":"T8","span":{"begin":573,"end":598},"obj":"Disease"},{"id":"T9","span":{"begin":586,"end":598},"obj":"Disease"},{"id":"T10","span":{"begin":603,"end":616},"obj":"Disease"},{"id":"T11","span":{"begin":620,"end":628},"obj":"Disease"},{"id":"T12","span":{"begin":698,"end":706},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004995"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004496"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0001134"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A11","pred":"mondo_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":76,"end":78},"obj":"http://www.ebi.ac.uk/efo/EFO_0000265"},{"id":"T2","span":{"begin":175,"end":176},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":432,"end":434},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T4","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T5","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T6","span":{"begin":603,"end":608},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T7","span":{"begin":603,"end":608},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":278,"end":289},"obj":"Chemical"},{"id":"T2","span":{"begin":513,"end":527},"obj":"Chemical"},{"id":"T3","span":{"begin":517,"end":527},"obj":"Chemical"},{"id":"T4","span":{"begin":532,"end":543},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A3","pred":"chebi_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":14,"end":38},"obj":"Disease"},{"id":"3","span":{"begin":42,"end":65},"obj":"Disease"},{"id":"15","span":{"begin":136,"end":160},"obj":"Disease"},{"id":"16","span":{"begin":162,"end":170},"obj":"Disease"},{"id":"17","span":{"begin":242,"end":250},"obj":"Species"},{"id":"18","span":{"begin":252,"end":260},"obj":"Disease"},{"id":"19","span":{"begin":377,"end":385},"obj":"Disease"},{"id":"20","span":{"begin":419,"end":430},"obj":"Disease"},{"id":"21","span":{"begin":448,"end":456},"obj":"Species"},{"id":"22","span":{"begin":586,"end":598},"obj":"Disease"},{"id":"23","span":{"begin":603,"end":616},"obj":"Disease"},{"id":"24","span":{"begin":620,"end":628},"obj":"Disease"},{"id":"25","span":{"begin":698,"end":706},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"tao:has_database_id","subj":"2","obj":"MESH:C000657245"},{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:D002318"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:C000657245"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"Tax:9606"},{"id":"A18","pred":"tao:has_database_id","subj":"18","obj":"MESH:C000657245"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"MESH:C000657245"},{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"MESH:D009205"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:9606"},{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"MESH:D006973"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:D006333"},{"id":"A24","pred":"tao:has_database_id","subj":"24","obj":"MESH:C000657245"},{"id":"A25","pred":"tao:has_database_id","subj":"25","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":66},"obj":"Sentence"},{"id":"T2","span":{"begin":67,"end":135},"obj":"Sentence"},{"id":"T3","span":{"begin":136,"end":251},"obj":"Sentence"},{"id":"T4","span":{"begin":252,"end":326},"obj":"Sentence"},{"id":"T5","span":{"begin":327,"end":458},"obj":"Sentence"},{"id":"T6","span":{"begin":459,"end":629},"obj":"Sentence"},{"id":"T7","span":{"begin":630,"end":707},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":42,"end":65},"obj":"Phenotype"},{"id":"T2","span":{"begin":419,"end":430},"obj":"Phenotype"},{"id":"T3","span":{"begin":586,"end":598},"obj":"Phenotype"},{"id":"T4","span":{"begin":603,"end":616},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001626"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0012819"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001635"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"ENG_RE_CONSENSUS","denotations":[{"id":"T14","span":{"begin":136,"end":160},"obj":"DOID_0080600"},{"id":"T1","span":{"begin":162,"end":170},"obj":"DOID_0080600"},{"id":"T2","span":{"begin":252,"end":260},"obj":"DOID_0080600"},{"id":"T15","span":{"begin":327,"end":355},"obj":"HP_0001626"},{"id":"T3","span":{"begin":377,"end":385},"obj":"DOID_0080600"},{"id":"T5","span":{"begin":419,"end":430},"obj":"DOID_820"},{"id":"T4","span":{"begin":419,"end":430},"obj":"HP_0012819"},{"id":"T6","span":{"begin":513,"end":527},"obj":"CHEBI_35457"},{"id":"T16","span":{"begin":532,"end":561},"obj":"CHEBI_61016"},{"id":"T9","span":{"begin":586,"end":598},"obj":"HP_0000822"},{"id":"T10","span":{"begin":586,"end":598},"obj":"DOID_10763"},{"id":"T11","span":{"begin":603,"end":616},"obj":"HP_0001635"},{"id":"T12","span":{"begin":620,"end":628},"obj":"DOID_0080600"},{"id":"T13","span":{"begin":698,"end":706},"obj":"DOID_0080600"}],"relations":[{"id":"R10","pred":"negative","subj":"T10","obj":"T6"},{"id":"R11","pred":"negative","subj":"T10","obj":"T6"},{"id":"R12","pred":"negative","subj":"T16","obj":"T9"},{"id":"R13","pred":"negative","subj":"T16","obj":"T11"},{"id":"R14","pred":"negative","subj":"T6","obj":"T10"},{"id":"R15","pred":"negative","subj":"T6","obj":"T11"},{"id":"R16","pred":"effect","subj":"T15","obj":"T3"},{"id":"R17","pred":"effect","subj":"T5","obj":"T3"},{"id":"R18","pred":"effect","subj":"T5","obj":"T12"},{"id":"R19","pred":"effect","subj":"T15","obj":"T12"},{"id":"R20","pred":"effect","subj":"T15","obj":"T13"},{"id":"R21","pred":"effect","subj":"T15","obj":"T2"},{"id":"R22","pred":"effect","subj":"T15","obj":"T1"},{"id":"R23","pred":"effect","subj":"T15","obj":"T14"},{"id":"R24","pred":"effect","subj":"T5","obj":"T13"},{"id":"R25","pred":"effect","subj":"T5","obj":"T2"},{"id":"R26","pred":"effect","subj":"T5","obj":"T1"},{"id":"R27","pred":"effect","subj":"T5","obj":"T14"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}

{"project":"ENG_NER_NEL_CONSENSUS","denotations":[{"id":"T39","span":{"begin":136,"end":160},"obj":"MESH:D000086382"},{"id":"T36","span":{"begin":136,"end":160},"obj":"DOID:0080600"},{"id":"T40","span":{"begin":162,"end":170},"obj":"MESH:D000086382"},{"id":"T5","span":{"begin":162,"end":170},"obj":"DOID:0080600"},{"id":"T41","span":{"begin":252,"end":260},"obj":"MESH:D000086382"},{"id":"T7","span":{"begin":252,"end":260},"obj":"DOID:0080600"},{"id":"T37","span":{"begin":278,"end":325},"obj":"MESH:D011945"},{"id":"T38","span":{"begin":327,"end":355},"obj":"HP:0001626"},{"id":"T42","span":{"begin":377,"end":385},"obj":"MESH:D000086382"},{"id":"T13","span":{"begin":377,"end":385},"obj":"DOID:0080600"},{"id":"T17","span":{"begin":419,"end":430},"obj":"MESH:D009205"},{"id":"T16","span":{"begin":419,"end":430},"obj":"HP:0012819"},{"id":"T15","span":{"begin":419,"end":430},"obj":"DOID:820"},{"id":"T20","span":{"begin":513,"end":527},"obj":"CHEBI:35457"},{"id":"T22","span":{"begin":532,"end":561},"obj":"CHEBI:61016"},{"id":"T25","span":{"begin":586,"end":598},"obj":"MESH:D006973"},{"id":"T24","span":{"begin":586,"end":598},"obj":"HP:0000822"},{"id":"T23","span":{"begin":586,"end":598},"obj":"DOID:10763"},{"id":"T29","span":{"begin":603,"end":616},"obj":"MESH:D006333"},{"id":"T28","span":{"begin":603,"end":616},"obj":"HP:0001635"},{"id":"T27","span":{"begin":603,"end":608},"obj":"MESH:D006321"},{"id":"T44","span":{"begin":620,"end":628},"obj":"MESH:D000086382"},{"id":"T31","span":{"begin":620,"end":628},"obj":"DOID:0080600"},{"id":"T33","span":{"begin":640,"end":648},"obj":"MESH:D012106"},{"id":"T43","span":{"begin":698,"end":706},"obj":"MESH:D000086382"},{"id":"T35","span":{"begin":698,"end":706},"obj":"DOID:0080600"}],"text":"The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.\nO Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares.\nCoronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}